Literature DB >> 8793571

Evaluation of patients with minimally obstructive coronary artery disease and angina.

D Hasdai1, C R Cannan, V Mathew, D R Holmes, A Lerman.   

Abstract

Atherosclerotic coronary artery disease is a progressive process adversely affecting the integrity of the coronary vasculature. In past years, most studies have focused on the morphological changes leading to compromised coronary blood flow in atherosclerosis. However, in recent years it has become apparent that abnormal coronary vasomotor regulation may precede or accompany gross morphological changes in coronary atherosclerotic disease. In fact, the pathophysiology of angina pectoris in many patients with risk factors for atherosclerosis and minimally obstructive disease may involve abnormal coronary vasomotor tone regulation. The aim of the present article is to describe a clinical approach to patients with angina pectoris and minimally obstructive coronary artery disease based on current knowledge of coronary vasomotor regulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8793571     DOI: 10.1016/0167-5273(95)02548-0

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  18 in total

Review 1.  The assessment of endothelial function in the cardiac catheterization laboratory in patients with risk factors for atherosclerotic coronary artery disease.

Authors:  D Hasdai; A Lerman
Journal:  Herz       Date:  1999-11       Impact factor: 1.443

2.  Inverse association of MRI-derived native myocardial T1 and perfusion reserve index in women with evidence of ischemia and no obstructive CAD: A pilot study.

Authors:  Jaime L Shaw; Michael D Nelson; Janet Wei; Manish Motwani; Sofy Landes; Puja K Mehta; Louise E J Thomson; Daniel S Berman; Debiao Li; C Noel Bairey Merz; Behzad Sharif
Journal:  Int J Cardiol       Date:  2018-06-22       Impact factor: 4.164

Review 3.  Microvascular coronary dysfunction in women: pathophysiology, diagnosis, and management.

Authors:  Kamlesh Kothawade; C Noel Bairey Merz
Journal:  Curr Probl Cardiol       Date:  2011-08       Impact factor: 5.200

Review 4.  The Potential of Oxygenation-Sensitive CMR in Heart Failure.

Authors:  Elizabeth Hillier; Matthias G Friedrich
Journal:  Curr Heart Fail Rep       Date:  2021-08-11

Review 5.  The Challenges of Prevention, Diagnosis and Treatment of Ischemic Heart Disease in Women.

Authors:  LaPrincess C Brewer; Anna Svatikova; Sharon L Mulvagh
Journal:  Cardiovasc Drugs Ther       Date:  2015-08       Impact factor: 3.727

6.  Patients With Coronary Endothelial Dysfunction Have Impaired Cholesterol Efflux Capacity and Reduced HDL Particle Concentration.

Authors:  Jeffrey S Monette; Patrick M Hutchins; Graziella E Ronsein; Jake Wimberger; Angela D Irwin; Chongren Tang; Jaskanwal D Sara; Baohai Shao; Tomas Vaisar; Amir Lerman; Jay W Heinecke
Journal:  Circ Res       Date:  2016-04-25       Impact factor: 17.367

Review 7.  Coronary microvascular dysfunction in women: an overview of diagnostic strategies.

Authors:  Sujith Kuruvilla; Christopher M Kramer
Journal:  Expert Rev Cardiovasc Ther       Date:  2013-11

8.  Is there a role for remote ischemic conditioning in preventing 5-fluorouracil-induced coronary vasospasm?

Authors:  Jun Chong; Andrew Fw Ho; Jonathan Yap; Heerajnarain Bulluck; Derek J Hausenloy
Journal:  Cond Med       Date:  2019-10

9.  Mortality in patients with microvascular disease.

Authors:  David S Marks; Surrendra Gudapati; L M Prisant; Brooke Weir; Caroline diDonato-Gonzalez; Jennifer L Waller; Jan L Houghton
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-06       Impact factor: 3.738

10.  Lack of correlation between the optimal glycaemic control and coronary micro vascular dysfunction in patients with diabetes mellitus: a cross sectional study.

Authors:  Luis Felipe Valenzuela-Garcia; Yasushi Matsuzawa; Jaskanwal D S Sara; Taek-Geun Kwon; Ryan J Lennon; Lilach O Lerman; Rafael J Ruiz-Salmeron; Amir Lerman
Journal:  Cardiovasc Diabetol       Date:  2015-08-14       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.